USA Tumor Ablation Report | Cetas Healthcare

September 2022

The USA Tumor Ablation report is the first ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Radiology departments from Academic Hospitals, Community Hospitals, Office Based Labs (OBL) and Private Hospitals in USA.

The report covers:

Tumor ablation devices: Microwave Ablation (MWA), Cryoablation, Radiofrequency Ablation (RFA), High Frequency Ultrasound (HIFU) and Irreversible Electroporation (IRE).
Procedure trends: by cancer type and modality/device type.

“I have good experience with Galil. I like the visualization of the iceball, it makes it very easy to visualize the procedure. I also like the efficacy and it is very easy to use.”

– Interventional Radiologist, Tumor Ablation USA

>60% of interventional oncology procedures are conducted at University Hospitals
~25% of all interventional oncology procedures are for liver cancer
~14% of Interventional Radiologists perform high-volume procedures (>80 procedures/year)

Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.Future trends such as immunotherapy used in combination with ablation technologies is gaining prominence. Acceptance of tumor ablation to treat cancer types such as breast cancer is expected to increase as clinical evidence suggests good patient outcomes.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such announcement of new clinical data from NAVBLATE study on biomicroscopically used microwave ablation (MWA) for treating malignant lung tumors by Medtronic; showcase of the TULSA-PRO thermal ultrasound-based treatment for patients with prostrate cancer and benign prostrate hyperplasia by Profound Medical are covered in the report

What’s in it for you?

This report will help tumor ablation devices companies understand the interventional oncology landscape, procedural and technology trends, the brand perception, and competitor activities in the USA.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the tumor ablation devices market.

The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model.
REPORT COST: 5,000 USD
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.

The United States Tumor Ablation Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2019-2022)

Privacy settings